As we step into 2025, Tekton Research is proud to reflect on a year filled with growth, innovation, and impactful contributions to clinical research. Tekton extends their gratitude to everyone who played a role in advancing their mission. From the dedicated staff and PI’s, to CRO and biopharma partners, and patients, who generously participated in trials–your commitment has been integral to driving progress in healthcare and drug development. Together, these collective efforts have made all of the achievements in 2024 possible, and Tekton looks forward to building on this momentum this year.
Investing in Tekton’s Teams
In 2024, Tekton Research not only expanded its site network and geographic reach, but also strengthened its operational capabilities and infrastructure to support continued growth. Key departments were strategically developed, fostering collaboration across all levels of the organization. The operational framework was refined to leverage specialized expertise, ensuring efficient and effective study delivery. Additionally, Tekton invested in technology enablement, implementing a centralized and unified platform to enhance operational management. Professional development remained a priority, reinforcing Tekton’s commitment to maintaining its position as a leader in the industry.
Expanding Tekton’s Reach
Tekton Research achieved significant milestones in expanding their network of research sites by partnering with outstanding investigators in underrepresented regions with limited access to clinical trials. Tekton’s expansion prioritizes geographic diversity and inclusivity, ensuring a more representative and balanced patient population reflective of the U.S. demographic. By focusing on areas not saturated with clinical research activity, Tekton is broadening access to innovative treatments for historically underserved communities. In 2024, they added 11 principal investigators and established a presence with 9 new sites in 4 cities, further enhancing Tekton’s reach and impact.
CNS: Advancing CNS Research
Tekton Research continued to expand its footprint in CNS research in 2024. To confirm their dedication to CNS, Jeffrey Zucker joined Tekton’s team to grow experience and capabilities. Jeffrey brings 28 years of CNS research to Tekton, bringing impactful results since he joined in April of 2024. One of Tekton’s esteemed principal investigators, Dr. David McCoy, led groundbreaking advancements, including being the first to enroll a participant in an Alzheimer’s study and ranking among the top enrollers. He was also awarded a second study in myasthenia gravis. Last year, Tekton welcomed Dr. Alex Reish, a migraine and chronic pain specialist in Boulder, CO, known for his expertise in reducing opioid use, and Dr. Amor Mehta, a prominent neurologist specializing in epilepsy, movement disorders, and Alzheimer’s disease in Marlboro, NJ. With several CNS feasibilities underway, Dr. Mehta is poised to support Tekton’s continued growth in this area. Tekton showcased their CNS expertise at prestigious conferences such as AAN, AAIC, CTAD, CNS Summit, and AES. Tekton was able to expand their capabilities in conducting more complex CNS trials through new partnerships and resources.
Cardiometabolic: Leading the fight against Cardiometabolic disorders
Tekton Research continued its pivotal work addressing cardiometabolic disorders- an urgent global health challenge. Under the leadership of esteemed principal investigators such as Pablo Mora, MD, a renowned subject matter expert, along with Muhammad Siddiqui, MD, Shahid Aziz, MD, and Samata Basani, MD, Tekton advanced medicine through innovative clinical trials. Complementing this network includes 14 general medicine physicians who play a vital role in supporting cardiometabolic research. Throughout 2024, Tekton strengthened their presence at key conferences, including EASD, ADA, Obesity Week, AACE, ATTD, and the Endocrine Society, furthering Tekton’s commitment to advancing medical knowledge in this critical field.
“Tekton is dedicated to advancing clinical research in the cardiometabolic space, thus supporting the development of therapies that will significantly improve lives. By connecting scientific discovery with patient care we are addressing some of the most prevalent health concerns, paving the way for a healthier future. ” – Alison Cooper, Vice President of Operations – Endocrinology
General Medicine: A Gateway to Multi-Therapeutic Advancements
Tekton’s general medicine sites demonstrated exceptional operational efficiency, delivering results across a wide range of therapeutic areas. Notably, Tekton Research surpassed enrollment targets for an Avian Influenza vaccine trial, achieving an impressive 170% enrollment. At the World Vaccine Congress, Tekton highlighted their expertise in infectious disease and vaccine studies, reinforcing leadership in this space. Tekton’s 11 general medicine sites, led by 14 highly experienced Principal Investigators, support a diverse portfolio of clinical trials across indications such as Type 2 diabetes, obesity, migraines, arthritis, depression, and hypertension. Furthermore, Tekton is actively expanding their capabilities in NASH/MASH research, with two established sites and a robust patient population ready to support studies launching in early 2025.
“I am thrilled to take part in our MASH/NASH expansion. There is a significant need in this indication and I hope that we can support remarkable growth and innovation in this field. It is a very exciting time to be involved in this type of research!” – Blaire Graham, Executive Director, Centralized Services
“Tekton is looking forward to a pivotal year by expanding not only capabilities within our General Medicine sites, but also by implementing technological advancements in 2025 ensuring trials conducted across the Tekton Network enroll quickly and collect data accurately, while continuing to provide robust centralized quality oversight.” – Taryn Collett, VP Clinical Operations, Vaccines and Infectious Diseases
What’s Ahead for 2025
As Tekton Research reflects on the milestones achieved in 2024, they are focused on an even brighter future. In 2025, Tekton will continue expanding into multi-therapeutic research, broadening their clinical trial offerings. Tekton’s strategic growth plan includes identifying new principal investigators and adding sites in regions currently outside Tekton’s geographic footprint. These new locations will align with their core therapeutic areas, ensuring seamless integration and enhanced trial support. Tekton looks forward to building on their success and sharing updates as these sites begin contributing to impactful clinical research.
“2024 has been a transformative year for Tekton Research. From expanding our site network to forging new partnerships and advancing clinical trials in diverse therapeutic areas, we are proud of the strides we’ve made to improve patient care and drive research forward. As we enter 2025, we remain committed to excellence, collaboration, and pushing the boundaries of what’s possible in clinical research.” – Kip McKenzie, CEO
At Tekton Research, their name reflects their mission–masters of our craft. With an unwavering commitment to excellence, Tekton remains dedicated to advancing clinical research and #MakingLifeBetter. Tekton thanks you for being part of their journey, as they look forward to a groundbreaking 2025!
